Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 8:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Rash Clear all
Not listed Phase 2 Interventional

A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris

NCT02395549
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.375% (w/w) MTC896 Gel, 0.75% (w/w) MTC896 Gel, 1.5% (w/w) MTC896 Gel, Vehicle Control Gel
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
16 Years to 65 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus

NCT05188521
View directory record Official record
Conditions
Cutaneous Lichen Planus
Interventions
Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
Drug
Lead sponsor
Aaron R. Mangold
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Results available

Analysis of Adherence in Subjects Undergoing Differin Gel, 0.1% Treatment of Moderate to Severe Acne Vulgaris

NCT00696449
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene, frequent visits, electronic reminder, Parent reminder, Standard of care
Drug · Behavioral
Lead sponsor
Wake Forest University
Other
Eligibility
13 Years to 18 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing OTC Acne Treatment to Prescription Regimen

NCT01237821
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BenzaClin, Effaclar
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults

NCT05080764
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 1h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient), 3h Incubation Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT), 3h Incubation Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
16 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Delray Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris

NCT02431052
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
28
States / cities
Mobile, Alabama • Encino, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 14, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX

NCT01692626
View directory record Official record
Conditions
Rash
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Topical Acne Regimens

NCT00913185
View directory record Official record
Conditions
Acne
Interventions
Acne Free, Proactiv
Drug
Lead sponsor
MedDerm Associates
Industry
Eligibility
13 Years to 45 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 14, 2026, 8:51 AM EDT
Completed No phase listed Observational

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

NCT00005781
View directory record Official record
Conditions
Dermatitis, Nevus, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 14, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infant Microbiome in Diaper Rash

NCT02893501
View directory record Official record
Conditions
Diaper Rash
Interventions
Not listed
Lead sponsor
Kimberly-Clark Corporation
Industry
Eligibility
9 Months to 12 Months
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Sep 14, 2026, 8:51 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption

NCT03115567
View directory record Official record
Conditions
Acneiform Rash, Papulopustular Eruption
Interventions
Triamcinolone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Double Blinded, Prospective, Randomized, Vehicle Controlled Multi-center Study of Photodynamic Therapy With Visonac® Cream in Patients With Acne Vulgaris

NCT01347879
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT, Vehicle cream with PDT
Drug
Lead sponsor
Photocure
Industry
Eligibility
12 Years to 35 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
15
States / cities
Oceanside, California • San Diego, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris

NCT01631474
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CB-03-01, Vehicle
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Sanford, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris

NCT00441415
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene BPO
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 35 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
4
States / cities
Santa Monica, California • Fridley, Minnesota • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Sep 14, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Research Core Dental Screening Protocol

NCT00090818
View directory record Official record
Conditions
Oral Mucosal Disease
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Generic Tretinoin 0.1% Microsphere Gel, 0.1% Retin-A Micro® and Placebo

NCT01135069
View directory record Official record
Conditions
Acne
Interventions
Tretinoin microsphere 0.1%, Brand Retin-A Micro tretinoin microsphere gel 0.1%, placebo microsphere gel
Drug
Lead sponsor
Spear Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Land O' Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

NCT02965456
View directory record Official record
Conditions
Acne
Interventions
IDP 121 Lotion, IDP-121 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
9 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
34
States / cities
Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Sep 14, 2026, 8:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Lyme Disease Lesions

NCT00132327
View directory record Official record
Conditions
Erythema Migrans Lesions, Erythema Migrans
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2018 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional

Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

NCT02293018
View directory record Official record
Conditions
Acne Vulgaris
Interventions
0.75% (w/w) MTC896 Gel Once Daily, 0.75% (w/w) MTC896 Gel Twice Daily, 1.5% (w/w) MTC896 Gel Once Daily
Drug
Lead sponsor
Mimetica Pty Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Austin, Texas • College Station, Texas • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fractional Resurfacing Device for Treatment of Acne Scarring

NCT00585286
View directory record Official record
Conditions
Acne, Scar
Interventions
10,600 nm fractional carbon dioxide laser system
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00612573
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day, Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
12 Years to 45 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
23
States / cities
Encino, California • Fremont, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT of an Oral Acne Supplement for Adult Women

NCT06097871
View directory record Official record
Conditions
Acne
Interventions
Skin Nutraceutical Supplement, Placebo pill
Dietary Supplement · Other
Lead sponsor
Nutraceutical Wellness Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 14, 2026, 8:51 AM EDT
Completed Phase 2 Interventional

Exploratory Study to Evaluate the Efficacy and Safety of CD07223 Gel in Subjects With Acne

NCT01106807
View directory record Official record
Conditions
Acne
Interventions
Epiduo vehicle gel, CD07223, Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 35 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
9
States / cities
Hot Springs, Arkansas • Louisville, Kentucky • Warren, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 14, 2026, 8:51 AM EDT